
    
      -  Single center, open label pilot study using 2.0mg intravitreal aflibercept injection.
           (IAI)

        -  20 subjects with active PDR to be randomized into 2 groups, i.e. groups A and B.

        -  Subjects in both arms will be followed-up every 4 weeks until week 52.

        -  The primary endpoint of the study will be at week 52.
    
  